Jazz Pharmaceuticals plc (JAZZ)

From the record

Jazz Pharmaceuticals plc's filings since 2017 show no warning events in the scan: no bankruptcy or receivership notice, no debt default notice, no exchange listing notice, no restatement warning, no auditor change, no material cyber incident and no late-report notice (its current reports).

From the record

Jazz Pharmaceuticals plc's 10 filed years say what it did: revenue went from $1.5 billion in fiscal 2016 to $4.3 billion in fiscal 2025, up 12.4% a year; it rose in 9 of 9 years; it never fell from a peak; net income was positive in 7 of 10 of those years (its annual reports).

From the record

Over the 3 fiscal years to 2025-12-31, Jazz Pharmaceuticals plc's diluted share count shrank about 0.8% a year, and dividends and buybacks returned about 18% of its operating cash flow over 3 years (its filed statements). Its officers and directors filed 67 sales (27 under scheduled 10b5-1 plans) and 0 purchases of their own stock on the open market in the year to 2026-11-10 (their Form 4 filings).

From the record

Return on equity: in the fiscal year ended 2025-12-31, Jazz Pharmaceuticals plc lost about 8 cents for every dollar of shareholders' money. Leverage: it owed about 63 cents per dollar of assets, and net share issuance: its share count shrank 7.6% over the year (the filed statements).

From the record

Jazz Pharmaceuticals plc's standing among 315 graded names in its industry family: revenue of $4.3 billion in fiscal 2025 ranks in the top 6% by size; a net margin of -8.3% ranks in the top 29%; revenue growth of 5.3% a year over the last 3 filed years ranks in the bottom 47% (its annual reports).

From the record

Jazz Pharmaceuticals plc's leadership, from its insiders' filings and its current reports: the chief executive on the record is Gala, Renee D (President & CEO, as filed), filing under that title since 2025-08-11, 1.3 years (bottom 17% of its family); the 19 officers and directors filing in the last fifteen months have been on the record a median of 7.3 years (top 26%); 9 officer or director changes were reported on Form 8-K since 2023-11-13, against the 19 people in charge now (bottom 47%; fewer changes for each person reads higher) (the Form 4 record, its Form 8-K reports). Years count from a person's first filing in the SEC's data sets, which begin in 2006, so each is a floor.

From the record

Jazz Pharmaceuticals plc's room to grow, from the newest filed statements (fiscal 2025): cash of $1.4 billion against debt of $4.3 billion leaves -25.2% of its assets as net cash, bottom 6% of its family; cash from operations less capital spending is 30.4% of revenue (top 7%); research spending of 18.3% of revenue (bottom 23%) (its annual report).

From the record

Jazz Pharmaceuticals plc's growth drivers, from the filed years to fiscal 2025: revenue grew 5.3% a year over the last three filed years against 12.4% over all 10, slowing (bottom 40% of its family); the newest year grew 4.9% (bottom 46%); research spending grew 9.9% a year (top 38%); capital spending grew 26.5% a year (top 21%) (its annual reports). Jazz Pharmaceuticals plc reported 13 product lines in fiscal 2025: Xywav at $1.7 billion (39%), Epidiolex Epidyolex at $1.1 billion (25%), Rylaze Enrylaze at $403 million (9%), and 10 more; 5 of 12 grew against the year before (its annual report).

From the record

Jazz Pharmaceuticals plc's newest year against its own record: revenue of $4.3 billion in fiscal 2025 came in 0.5% below the $4.3 billion its prior three years' pace pointed to (top 47% of its family); net income of $356 million against a prior three-year average of $250 million (bottom 7%); a net margin of -8.3% against 6.2% before (bottom 28%) (its annual reports).